These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19164457)

  • 1. Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?
    Loriot Y; Mordant P; Deutsch E
    Ann Oncol; 2009 Mar; 20(3):596-7; author reply 597. PubMed ID: 19164457
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides.
    Dias N; Stein CA
    Eur J Pharm Biopharm; 2002 Nov; 54(3):263-9. PubMed ID: 12445555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].
    Lebedeva IV; Staĭn SA
    Mol Biol (Mosk); 2000; 34(6):1025-38. PubMed ID: 11186002
    [No Abstract]   [Full Text] [Related]  

  • 4. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Bcl-2 family in cancer therapy.
    Papadopoulos K
    Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
    Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancements of antisense oligonucleotides in treatment of breast cancer.
    Yang SP; Song ST; Song HF
    Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design of antisense oligodeoxynucleotide targeting at bcl-2 mRNA and observation on its effect on the sensitivity of leukemia cells to arabinosyl cytosine].
    Lei XY; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):41-4. PubMed ID: 12667288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats.
    Baba M; Iishi H; Tatsuta M
    Int J Cancer; 2000 Jan; 85(2):260-6. PubMed ID: 10629087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 family members as molecular targets in cancer therapy.
    Marzo I; Naval J
    Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.